Skip to main content
Harbin Pharmaceutical Group Co.,Ltd. logo

Harbin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 600664 ISIN · CNE0000009T3 LEI · 300300G0L086UJ23MI26 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,827 across all filing types
Latest filing 2019-03-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600664

About Harbin Pharmaceutical Group Co.,Ltd.

https://www.hayao.com/

Harbin Pharmaceutical Group Co., Ltd. specializes in the research, development, manufacture, and distribution of a diverse range of pharmaceutical and healthcare products. The company's portfolio includes antibiotics, over-the-counter (OTC) medicines, health supplements, traditional Chinese medicines, and animal health products. It operates through several specialized subsidiaries and maintains a significant presence in the production of penicillins and cephalosporins. A key strategic focus involves the health and nutrition sector, bolstered by the acquisition of global nutrition brand GNC. The company leverages large-scale manufacturing capabilities and an extensive distribution network to serve both domestic and international markets. Its operations emphasize technological innovation and quality control across its integrated supply chain, from raw material production to finished dosage forms.

Recent filings

Filing Released Lang Actions
关于修改《公司章程》的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the amendment of the company's Articles of Association (公司章程). It details changes in registered capital and total shares, approved by the board and pending shareholder approval. It is not a full financial report, audit, or earnings release, nor is it a notice of voting results or a proxy solicitation. It is a regulatory announcement about governance documents and capital changes but does not fit the exact category of Share Issue/Capital Change (SHA) because it focuses on the amendment of the Articles of Association rather than a direct capital transaction. The best fitting category is Regulatory Filings (RNS) as a general regulatory announcement that does not neatly fit other categories.
2019-03-15 Chinese
独立董事关于公司对外担保情况的专项说明及独立意见
Audit Report / Information Classification · 95% confidence The document is a special statement and independent opinion by independent directors regarding the company's external guarantees, referencing regulatory notices from the China Securities Regulatory Commission and the company's 2018 audit report. It does not contain full financial statements or detailed audit results but rather a compliance and opinion statement on a specific issue (external guarantees). This fits the category of Audit Report / Information (AR), which includes standalone audit-related reports and applied accounting principles, excluding full annual reports. The document length is short but contains substantive content beyond a mere announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). FY 2018
2019-03-15 Chinese
独立董事关于公司2018年度利润分配的预案的独立意见
Notice of Dividend Amount Classification · 95% confidence The document is an independent opinion from the independent directors regarding the company's 2018 profit distribution plan. It discusses the audited net profit, retained earnings, dividend distribution, and the decision not to distribute profits or convert capital reserves into shares. This is a formal statement related to dividend policy and profit distribution, but it is not a full annual report or earnings release. It is a formal declaration related to dividend decisions and shareholder interests, fitting the category of Notice of Dividend Amount (DIV). The document length is short and focused on dividend distribution, not a full financial report or audit report.
2019-03-15 Chinese
独立董事关于公司2019年日常关联交易预计的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on the company's 2019 daily related-party transactions forecast. It references compliance with company law, stock exchange listing rules, and internal company regulations. The content is a formal opinion on a specific agenda item related to related-party transactions, not a full financial report or audit. It does not contain financial statements or detailed financial data, nor is it an announcement of voting results or management changes. It is a regulatory compliance-related statement, fitting best under Regulatory Filings (RNS) as it does not match other specific categories like Annual Report, Audit Report, or Management Reports.
2019-03-15 Chinese
2018年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2018 by Harbin Pharmaceutical Group Co., Ltd. It details the independent directors' activities, attendance at meetings, opinions on key matters such as external guarantees, appointment of auditors, profit distribution, stock repurchase, related party transactions, internal control, and committee work. The content is a detailed narrative of management oversight and governance activities by the independent directors rather than a full financial report or audit report. It is not an annual report (10-K), audit report (AR), or interim report (IR). It is also not a simple announcement or voting result. The document focuses on board/management information, specifically the independent directors' duties and opinions, which fits best under Board/Management Information (MANG). The length and detail confirm it is a substantive report, not a brief announcement or certification. Therefore, the classification is MANG with high confidence.
2019-03-15 Chinese
2018年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2018 年度内部控制评价报告' which translates to '2018 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2018. The content includes detailed descriptions of internal control scope, evaluation criteria, defect classifications, and remediation status. It is a comprehensive report on internal control evaluation rather than a brief announcement or certification. The document length is 3912 characters, which is relatively short but contains substantive content about internal control evaluation, not just a notice or certification. This type of report fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, including internal control evaluations. It is not an Annual Report (10-K) as it does not cover full financial performance, nor is it a Regulatory Filing (RNS) or Report Publication Announcement (RPA) since it contains detailed evaluation content. Therefore, the classification is AR with high confidence. FY 2018
2019-03-15 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.